30 related articles for article (PubMed ID: 15288287)
1. Challenges in the gynecologic care of premenopausal women with breast cancer.
Bakkum-Gamez JN; Laughlin SK; Jensen JR; Akogyeram CO; Pruthi S
Mayo Clin Proc; 2011 Mar; 86(3):229-40. PubMed ID: 21307388
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
Vehmanen L; Elomaa I; Blomqvist C; Saarto T
J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
[TBL] [Abstract][Full Text] [Related]
4. [A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].
Hisamatsu K; Iwamori S; Minami K; Tanabe K; Ota K; Akiyama H
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1327-30. PubMed ID: 9279354
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cysts in tamoxifen-treated women with breast cancer.
Inal MM; Incebiyik A; Sanci M; Yildirim Y; Polat M; Pilanci B; Nayki C; Camuzcuoğlu H
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):104-6. PubMed ID: 15866095
[TBL] [Abstract][Full Text] [Related]
6. LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen.
Berlière M; Galant C; Marques G; Piette P; Duck L; Fellah L; Donnez J; Machiels JP
Eur J Cancer; 2004 Aug; 40(12):1855-61. PubMed ID: 15288287
[TBL] [Abstract][Full Text] [Related]
7. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives.
Del Mastro L; Levaggi A; Giraudi S; Pronzato P
Cancer Treat Rev; 2011 May; 37(3):208-11. PubMed ID: 20724078
[TBL] [Abstract][Full Text] [Related]
8. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
Parton M; Smith IE
J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
[No Abstract] [Full Text] [Related]
9. [Hormone therapy in breast cancer: the end of tamoxifen?].
Delozier T
Bull Cancer; 2005 Feb; 92(2):142-50. PubMed ID: 15749643
[TBL] [Abstract][Full Text] [Related]
10. Polypoid endometriosis and other benign gynaecological complications associated with Tamoxifen therapy-a case to illustrate features on magnetic resonance imaging.
Kraft JK; Hughes T
Clin Radiol; 2006 Feb; 61(2):198-201. PubMed ID: 16439226
[No Abstract] [Full Text] [Related]
11. Adjuvant therapy for premenopausal patients with early breast cancer.
Kurebayashi J
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]